TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16046981
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEG‐E with a regular diet the day before colonoscopy followed by another 2 L PEG‐E on the day of the procedure (Group B)
Study: 16046981
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L PEG‐E with a liquid diet the day before colonoscopy (Group A)
Study: 10588465
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (daily intake: 216 mg eicosapentaenoic acid, 140 mg docosahexaenoic acid, 390 mg gamma‐linolenic acid, and 3480 mg linoleic acid)
Study: 8466726
Drug: Isradipine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 1.25 mg twice daily
Study: 1673616
Drug: Isradipine combined
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine combined with 1 mg/day bopindolol
Study: 7282610
Drug: Increasing amounts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing amounts of carbohydrate (88 to 648 g carbohydrate/day)
Study: 31971089
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (4000 IU of Vit D3 daily for 4 weeks)
Study: 29260292
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (4000 IU daily for 3 years)
Study: 23018287
Drug: Metronome sound-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronome sound-guided group (MG)
Study: 16673797
Drug: Metronidazole cream
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole cream (0.75% and 1%)
Study: 16673797
Drug: Metronidazole gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole gel (0.75% and 1%)
Study: 16673797
Drug: Metronidazole lotion
Normalized name: metronidazole Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole lotion (0.75% and 1%)
Study: 7631329
Drug: Active blood
Normalized name: Accu-Chek Active Blood Glucose Meter Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active blood pressure treatment
Study: 2115856
Drug: 80 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 micrograms intravenous GHRH
Study: 7308953
Drug: Indomethacin retard,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin retard, applied twice daily (43% of cases) or sometimes (14%)
Study: 29596010
Drug: Higher intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher intensity whole body vibration (amplitude 8.82 mm, g force 2.76)
Study: 29596010
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity whole body vibration (amplitude 4.53 mm, g force 2.21)
Study: 30591069
Drug: Brief medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief medication review combined with a standardised communication strategy at hospital discharge
Study: 19366435
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration
Study: 28922968
Drug: N-acetylcysteine (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (2400 mg)
Study: 22549117
Drug: No compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: No compound (control)
Study: 19027366
Drug: Oestrogen/progestin hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen/progestin hormone therapy
Study: 19027366
Drug: Selective oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective oestrogen receptor modulators
Study: 11863154
Drug: 4.4 ml
Normalized name: APONVIE 32 MG in 4.4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 ml lidocaine with 1:80,000 epinephrine
Study: 11863154
Drug: 4.4 ml
Normalized name: APONVIE 32 MG in 4.4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 ml 3% prilocaine with 0.031 U/ml felypressin
Study: 10445367
Drug: NaF gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF gel (1%)
Study: 10445367
Drug: SnF2 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SnF2 gel (1%)
Study: 3668844
Drug: Diazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (20 mg)
Study: 31652344
Drug: Zolpidem hemitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem hemitartrate formulation (5 mg orodispersible tablet)
Study: 31652344
Drug: Zolpidem hemitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem hemitartrate formulation (5 mg sublingual tablet)
Study: 8378946
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg/d
Study: 23915042
Drug: Placebo analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo analgesic treatments (choice between treatments)
Study: 23915042
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (choice of treatment)
Study: 23915042
Drug: Auditory discomfort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory discomfort paradigm (choice between treatments)
Study: 20689466
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestogen therapy
Study: 19298337
Drug: 14-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14-day regimen with 500 mg clarithromycin b.i.d., 500 mg metronidazole t.i.d., and 500 mg amoxicillin t.i.d.
Study: 19298337
Drug: 10-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-day regimen containing 500 mg clarithromycin b.i.d., 1 g amoxicillin b.i.d., and 20 mg omeprazole b.i.d.
Study: 19298337
Drug: 14-day clarithromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day clarithromycin, metronidazole, and amoxicillin regimen
Study: 19298337
Drug: 10-day clarithromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day clarithromycin, amoxicillin, and omeprazole regimen
Study: 19298337
Drug: Participants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with atrophic gastritis receiving clarithromycin, metronidazole, and amoxicillin
Study: 19298337
Drug: Participants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with atrophic gastritis receiving clarithromycin, amoxicillin, and omeprazole
Study: 9519749
Drug: Picotamide, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide, 300 mg, 3 tablets/day
Study: 9519749
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 tablets/day
Study: 2699544
Drug: Kanamicine sulphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanamicine sulphate daily for 6 days followed by polidesossiribonucleotide for 24 days
Study: 26635079
Drug: 16 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g/d prebiotic supplementation
Study: 23605175
Drug: Mindfulness intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness intervention (eight weekly individual phone sessions)
Study: 14669032
Drug: Therapy (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy (not specified)
Study: 8952010
Drug: Vigabatrin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 3 g/day
Study: 1893304
Drug: Prazosin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (10 mg bid, titrated to 18.6 +/- 0.7 mg/day)
Study: 6407410
Drug: Weekly exchange
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly exchange of CVC via a guidewire
Study: 25645091
Drug: Oxalobacter formigenes
Normalized name: Oxalobacter formigenes
DrugBank: Oxabact (DB17676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxalobacter formigenes (700 million, twice a day)
Study: 25645091
Drug: Potassium magnesium
Normalized name: POTASSIUM MAGNESIUM SULFATE
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium magnesium citrate (30 mEq, twice a day)
Study: 23539907
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg/16 mg as add-on therapy to ACE-inhibitors
Study: 20592724
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg
Study: 19011428
Drug: Ziprasidone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (40 mg single dose)
Study: 19011428
Drug: Haloperidol (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (7.5 mg single dose)
Study: 19011428
Drug: Ziprasidone (steady-state
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (steady-state treatment)
Study: 12745490
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray alone
Study: 12745490
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (nicotine patch + nicotine nasal spray)
Study: 12745490
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch alone, Nicotine nasal spray alone, Combination therapy
Study: 8627439
Drug: Preservative-free topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free topical ointment therapy
Study: 8627439
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no topical treatment or as-needed therapy with a water-in-oil emollient)
Study: 2741976
Drug: Propranolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.1 mg/kg intravenously)
Study: 3922732
Drug: Metoprolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.15 mg/kg intravenously)
Study: 29316164
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly plus dapagliflozin
Study: 27391640
Drug: Once-daily 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily 5% minoxidil topical foam (MTF)
Study: 27391640
Drug: Twice-daily 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily 2% minoxidil topical solution (MTS)
Study: 24641892
Drug: DepoDur (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoDur (extended-release epidural morphine)
Study: 23310938
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg propofol (PG)
Study: 23310938
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg thiopentone (TG)
Study: 16867927
Drug: Slow-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release morphine
Study: 24140630
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg per day
Study: 1592970
Drug: Dentifrice with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice with 1000 micrograms F/g
Study: 1592970
Drug: Dentifrice with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice with 1500 micrograms F/g
Study: 1592970
Drug: Dentifrice with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice with 2500 micrograms F/g
Study: 1592970
Drug: Dentifrice with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice with 0 micrograms F/g (control)
Study: 1592970
Drug: Fluoride-containing dentifrices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-containing dentifrices (1000, 1500, 2500 micrograms F/g)
Study: 6329092
Drug: pivmecillinam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam 400 mg every 6 h for 5 days
Study: 6329092
Drug: ampicillin 500
Normalized name: ampicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin 500 mg every 6 h for 5 days
Study: 6329092
Drug: pivmecillinam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam 400 mg every 6 h for 5 days (excluding resistant strains)
Study: 6329092
Drug: ampicillin 500
Normalized name: ampicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin 500 mg every 6 h for 5 days (excluding resistant strains)
Study: 6329092
Drug: pivmecillinam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam 400 mg every 6 h for 5 days (susceptible strains)
Study: 6329092
Drug: ampicillin 500
Normalized name: ampicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin 500 mg every 6 h for 5 days (susceptible strains)
Study: 30799839
Drug: Osteopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic treatment coupled with lactation consultation
Study: 22244049
Drug: Iferanserin 10
Normalized name: Iferanserin
DrugBank: Iferanserin (DB11686)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iferanserin 10 mg BID
Study: 27547421
Drug: Voglibose 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 0.2 mg three times a day
Study: 11958305
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous insulin infusion with dextrose 5%‐based cardioplegic solution
Study: 11958305
Drug: Sliding scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding scale insulin treatment with normal saline 0.9%‐based cardioplegic solution
Study: 1356117
Drug: Budesonide (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (0.4 mg at 8 AM and 8 PM)
Study: 1356117
Drug: Bambuterol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol (20 mg at 8 PM)
Study: 30189251
Drug: Topical postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical postoperative tobramycin-dexamethasone
Study: 26659113
Drug: Treatment-as-usual (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (control group, n=32)
Study: 24781441
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (405 mg/4 weeks)
Study: 24781441
Drug: Oral olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral olanzapine (10 mg/d)
Study: 22613240
Drug: Circuit class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circuit class therapy with heart rate monitor feedback
Study: 22613240
Drug: Circuit class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circuit class therapy without heart rate monitor feedback (Control)
Study: 17349034
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment for community acquired pneumonia
Study: 17349034
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) treatment for community acquired pneumonia
Study: 11323149
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg imipramine
Study: 2161692
Drug: hPTH 1‐38
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH 1‐38 (400 IU/day subcutaneous injection)
Study: 2161692
Drug: hPTH 1‐38
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH 1‐38 (0.5 U/kg/h intravenous infusion)
Study: 2161692
Drug: hPTH 1‐38
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH 1‐38 (intermittent treatment)
Study: 2161692
Drug: hPTH 1‐38
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH 1‐38 therapy
Study: 2161692
Drug: hPTH 1‐38
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH 1‐38 treatment
Study: 23889806
Drug: Paricalcitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (2 μg/day)
Study: 21827773
Drug: Gallic acid
Normalized name: gallic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallic acid (GA) supplementation (12.8 mg/person/d) for three days
Study: 14709514
Drug: Different facemasks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different facemasks used for aerosol medication delivery
Study: 9228352
Drug: Albuterol solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol solution, 5 mg via nebulizer (Puritan‐Bennett Raindrop) impelled with oxygen at 8 L/min
Study: 9228352
Drug: Albuterol, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol, 400 microg via CFCMDI attached to a 145‐mL valved aerosol holding chamber (Aerochamber)
Study: 9228352
Drug: Albuterol powder,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol powder, 400 microg by Rotahaler
Study: 8028563
Drug: embovin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: embovin (10 mg/kg)
Study: 8028563
Drug: combatrin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: combatrin (10 mg/kg)
Study: 29475446
Drug: n-3 LCPUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 LCPUFA supplements
Study: 27456448
Drug: Intensive physiotherapy
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive physiotherapy (three times daily)
Study: 27456448
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care physiotherapy (daily)
Study: 25573904
Drug: Ritonavir powder
Normalized name: ritonavir Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir powder formulation in water under fasting, moderate-fat or high-fat conditions
Study: 25573904
Drug: Ritonavir powder
Normalized name: ritonavir Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir powder formulation in chocolate milk or pudding under moderate-fat conditions
Study: 25573904
Drug: Ritonavir oral
Normalized name: ritonavir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir oral solution under moderate-fat conditions
Study: 25573904
Drug: Ritonavir powder
Normalized name: ritonavir Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir powder formulation in infant formula or apple sauce under moderate-fat conditions
Study: 16248249
Drug: Integrative traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative traditional and Western medicine (conventional Western medicine combined with Chinese compound recipe)
Study: 16248249
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine alone
Study: 9715310
Drug: Picrorhiza kurroa
Normalized name: PICRORHIZA KURROA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picrorhiza kurroa (Pk) root powder 375 mg three times a day for 2 weeks
Study: 6828609
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of caffeine
Study: 6828609
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of caffeine
Study: 6828609
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of caffeine
Study: 24615500
Drug: Everolimus (EVE)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVE) 10 mg/day + Exemestane (EXE) 25 mg/day
Study: 24615500
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) + Exemestane (EXE) 25 mg/day
Study: 19670432
Drug: microS (MRX‐801)
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: microS (MRX‐801) infusion over 90 minutes (Cohort 1, 1.4ml)
Study: 19670432
Drug: microS (MRX‐801)
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: microS (MRX‐801) infusion over 90 minutes (Cohort 2, 2.8ml)
Study: 19670432
Drug: microS (MRX‐801)
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: microS (MRX‐801) infusion over 90 minutes (Cohort 1)
Study: 19670432
Drug: microS (MRX‐801)
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: microS (MRX‐801) infusion over 90 minutes (Cohort 2)
Study: 16140896
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg riboflavin + 20 mg iron (n = 83)
Study: 16140896
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zinc (n = 83)
Study: 16140896
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg riboflavin (control, n = 82)
Study: 12151469
Drug: iloprost (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: iloprost (2.5 or 5.0 microg, six or nine times per day; median inhaled dose, 30 microg per day)
Study: 9935128
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 100 mg/d orally on days 1-10 of the menstrual cycle
Study: 9935128
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg orally twice daily
Study: 9935128
Drug: Triptorelin 3.75
Normalized name: triptorelin 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 3.75 mg IM every 28 days
Study: 7486235
Drug: E5510 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5510 4 mg
Study: 7486235
Drug: E5510 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5510 2 mg
Study: 9262254
Drug: Aspirin 324
Normalized name: aspirin 324 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 324 mg
Study: 2248075
Drug: Moclobemide (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (150-300 mg daily)
Study: 2248075
Drug: Tranylcypromine (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine (15-30 mg daily)
Study: 25399316
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (250 mg capsules every 8 h)
Study: 25399316
Drug: Ginger (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (250 mg capsules every 6 h)
Study: 24512486
Drug: Octreotide 100
Normalized name: 1 ML octreotide 100 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 100 μg sc
Study: 24512486
Drug: Control (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (before administration of octreotide)
Study: 19346521
Drug: Non-ARB-based pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ARB-based pharmacotherapy
Study: 17277998
Drug: Aspirin (81-325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81-325 mg daily for at least a week)